The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants ...

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as ...

A single booster shot of MenQuadfi can be given to people ages 13 years or older who are at a continued risk of IMD if it’s been at least three years since their last meningococcal vaccine.

The FDA has recently approved MenQuadfi, a meningococcal conjugate vaccine that protects against serogroups A, C, Y and W. The approval is for patients aged 2 years and older, according to a press ...

Dublin, June 12, 2020 (GLOBE NEWSWIRE) -- The "MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) Drug Overview" report has been added to ResearchAndMarkets.com's offering.

European Commission approves MenQuadfi ®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older EC approval based on robust data from seven ...

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as young as six weeks, expanding its previous label indicated for ...